Real-time enrollment status for this advanced or metastatic er+ her2- breast cancer (mbc) clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 8:49 AM UTC
| NCT Number | NCT06784193 |
| Recruiting Status | Recruiting |
| Condition | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) |
| Phase | Clinical Trial |
| Target Enrollment | 180 participants |
| Active Locations | 7 sites in the US |
| Sponsor | Olema Pharmaceuticals, Inc. |
| Last Updated on CT.gov | October 10, 2025 (Oct 10, 2025) |
As of July 13, 2026: Clinical trial NCT06784193 is currently recruiting participants. This clinical trial study for advanced or metastatic er+ her2- breast cancer (mbc) is actively seeking new participants at 7 locations across the United States. The study is sponsored by Olema Pharmaceuticals, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06784193 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 7 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06784193 was last updated Oct 10, 2025 (October 10, 2025). HelloStudys verifies this status automatically.